GAS2L1 and pancreatic neoplasm: Therefore, the overexpression of GAS2L1 in pancreatic CTCs and its utility in combination with EPCAM as a cell surface marker represent a promising approach for detecting and isolating pancreatic CTCs, and highlights the potential of GAS2L1 as a novel biomarker for pancreatic cancer.